The FDA issued a Drug Safety Communication highlighting severe pruritus following discontinuation of cetirizine and levocetirizine, with reported cases impacting quality of life and functional capacity, and potential reoccurrence upon retrying the medications. The FDA is implementing new warnings and clinical recommendations to address this issue, emphasizing the need for healthcare professionals to discuss discontinuation risks with patients.

Source: FDA